行業指南

藥物發現中的人工智慧

AI methods can support several stages of drug research, including protein-structure prediction, molecular property prediction, virtual screening and molecule generation.

聆聽此指南AI 語音敘述 · ~2 min

本頁閱讀時間約2分鐘
  1. 概述
  2. 深入探討
  3. 現實世界的實施
  4. 人工智慧在藥物發現的未來
  5. 付諸實踐
  6. 不斷探索
  7. 常見問題

概述

A model result is a research hypothesis or prioritization signal, not evidence of clinical safety or efficacy.

深入探討

AlphaFold predicts protein structures, while AlphaFold 3 extends structure prediction to biomolecular complexes involving proteins, nucleic acids, small molecules and other components. MoleculeNet describes machine-learning tasks over molecular representations including graphs and SMILES. Deep Docking illustrates one virtual-screening approach that uses predictions to reduce how many compounds require expensive docking calculations. DeepTox and later molecular-generation studies address toxicity prediction and candidate generation; these methods do not establish a compound’s safety, efficacy or clinical success. FDA describes preclinical testing and an IND process before clinical studies in people.

現實世界的實施

Using AlphaFold to predict protein structures, as reported in its paper and resource database.

Using AlphaFold 3 to predict structures and interactions among proteins, nucleic acids, small molecules and other biomolecules.

Representing molecules as graphs or SMILES strings in molecular-learning benchmarks.

Using virtual screening to prioritize compounds for experimental testing, with predictions treated as uncertain.

人工智慧在藥物發現的未來

Evaluate screening and generation methods on prospective, target-relevant data and report experimental confirmation rates. Follow regulatory requirements for preclinical and human research; remove candidates only after evidence appropriate to the task, rather than treating model scores as final decisions.

付諸實踐

為什麼這很重要

  • 背景與規則. 產業背景決定了人工智慧創意能否與現實接觸。
  • 品質管控. 領域約束會影響可接受的錯誤率和監督模型。
  • 配裝選擇. 成功的部署使技術能力與第一線工作流程保持一致。

留意

  • 監理要求可能會使原本強大的原型失效。
  • 歷史資料可能會編碼損害特定社區的偏見。
  • 遺留系統可能會造成整合瓶頸和隱性成本。

後續步驟

  1. 讓領域專家參與從問題框架到評估的整個過程。
  2. 在啟動前設計審計追蹤和文件。
  3. 儘早驗證合規性和安全義務。
  4. 分階段推出,並有明確的停止和回滾標準。

不斷探索

免費電子報

獲取每日 AI 簡報

每個工作日上午提供三則經過驗證的 AI 新聞,以淺顯易懂的英文撰寫。永久免費,無廣告。

每個工作日一封電子郵件。一鍵取消訂閱。我們絕不出售或分享您的地址。

測試一下自己

Take the AI in Drug Discovery quiz

每個答案皆有即時回饋,通過課程後可獲得具備可驗證 ID 的可分享證書。

開始測驗

支持免費的 AI 教育。AI Understanding 是一個 501(c)(3) 非營利組織——絕無廣告,絕無付費牆。 捐款

常見問題

What is AI in Drug Discovery?

AI methods can support several stages of drug research, including protein-structure prediction, molecular property prediction, virtual screening and molecule generation. A model result is a research hypothesis or prioritization signal, not evidence of clinical safety or efficacy.

DeepMind 的 AlphaFold 在幫助藥物發現方面取得了哪些成就?

AlphaFold 使用深度學習大規模預測蛋白質 3D 結構,為研究人員提供了先前需要多年實驗的結構藍圖。

機器學習模型中分子通常如何表示?

分子本質上是由圖神經網路處理的圖(原子=節點,鍵=邊),或編碼為序列模型的SMILES字串。

什麼是人工智慧藥物發現中的「虛擬篩選」?

虛擬篩選使用模型在電腦上對龐大的分子庫進行評分,因此只有最優秀的候選者才會在實驗室中進行製造和測試。

ADME 或毒性預測在早期候選分子評估時能提供什麼?

Computational ADME/toxicity predictions can prioritize compounds for follow-up; they are model outputs and do not establish safety or replace experimental testing.

哪些生成式人工智慧技術用於設計新穎的分子?

VAE 和擴散模型等生成模型從學習的化學空間中取樣新結構,優化所需的特性。